Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Price, Quote, News and Overview

NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD

2.33  -3.94 (-62.84%)

After market: 2.4 +0.07 (+3%)

RCKT Quote, Performance and Key Statistics

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (5/27/2025, 8:00:01 PM)

After market: 2.4 +0.07 (+3%)

2.33

-3.94 (-62.84%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High26.98
52 Week Low2.19
Market Cap251.03M
Shares107.74M
Float103.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/amc
IPO02-18 2015-02-18


RCKT short term performance overview.The bars show the price performance of RCKT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

RCKT long term performance overview.The bars show the price performance of RCKT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RCKT is 2.33 USD. In the past month the price decreased by -67.46%. In the past year, price decreased by -89.07%.

ROCKET PHARMACEUTICALS INC / RCKT Daily stock chart

RCKT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About RCKT

Company Profile

RCKT logo image Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Company Info

ROCKET PHARMACEUTICALS INC

9 Cedarbrook Drive

Cranbury NEW JERSEY 08512 US

CEO: Gaurav Shah

Employees: 299

RCKT Company Website

RCKT Investor Relations

Phone: 16464409100

ROCKET PHARMACEUTICALS INC / RCKT FAQ

What is the stock price of ROCKET PHARMACEUTICALS INC today?

The current stock price of RCKT is 2.33 USD. The price decreased by -62.84% in the last trading session.


What is the ticker symbol for ROCKET PHARMACEUTICALS INC stock?

The exchange symbol of ROCKET PHARMACEUTICALS INC is RCKT and it is listed on the Nasdaq exchange.


On which exchange is RCKT stock listed?

RCKT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ROCKET PHARMACEUTICALS INC stock?

24 analysts have analysed RCKT and the average price target is 39.03 USD. This implies a price increase of 1575.19% is expected in the next year compared to the current price of 2.33. Check the ROCKET PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROCKET PHARMACEUTICALS INC worth?

ROCKET PHARMACEUTICALS INC (RCKT) has a market capitalization of 251.03M USD. This makes RCKT a Micro Cap stock.


How many employees does ROCKET PHARMACEUTICALS INC have?

ROCKET PHARMACEUTICALS INC (RCKT) currently has 299 employees.


What are the support and resistance levels for ROCKET PHARMACEUTICALS INC (RCKT) stock?

ROCKET PHARMACEUTICALS INC (RCKT) has a resistance level at 6.68. Check the full technical report for a detailed analysis of RCKT support and resistance levels.


Is ROCKET PHARMACEUTICALS INC (RCKT) expected to grow?

The Revenue of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 115254% in the next year. Check the estimates tab for more information on the RCKT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROCKET PHARMACEUTICALS INC (RCKT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROCKET PHARMACEUTICALS INC (RCKT) stock pay dividends?

RCKT does not pay a dividend.


When does ROCKET PHARMACEUTICALS INC (RCKT) report earnings?

ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of ROCKET PHARMACEUTICALS INC (RCKT)?

ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.63).


What is the Short Interest ratio of ROCKET PHARMACEUTICALS INC (RCKT) stock?

The outstanding short interest for ROCKET PHARMACEUTICALS INC (RCKT) is 12.11% of its float. Check the ownership tab for more information on the RCKT short interest.


RCKT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RCKT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RCKT. The financial health of RCKT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RCKT Financial Highlights

Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.63. The EPS increased by 8.36% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -54.77%
ROE -62.61%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%15.15%
Sales Q2Q%N/A
EPS 1Y (TTM)8.36%
Revenue 1Y (TTM)N/A

RCKT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to RCKT. The Buy consensus is the average rating of analysts ratings from 24 analysts.

For the next year, analysts expect an EPS growth of 12.95% and a revenue growth 115254% for RCKT


Ownership
Inst Owners104.13%
Ins Owners3.11%
Short Float %12.11%
Short Ratio4.18
Analysts
Analysts84.17
Price Target39.03 (1575.11%)
EPS Next Y12.95%
Revenue Next Year115254%